Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591888 | 0.83 | EGFR (0.50) | PDGFRBPDGFRASRCTGFBR1EGFR | |
| SCHEMBL4481865 | 0.82 | SRC (0.60) | PDGFRBPDGFRASRCTGFBR1EGFR | |
| SCHEMBL21591890 | 0.82 | SMN1; SMN2 (0.44) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29362546 | 0.82 | SMN1; SMN2 (0.44) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL167759 | 0.78 | PDGFRB (0.71) | PDGFRBPDGFRAEGFRKDRFGFR2 | |
| SCHEMBL4400367 | 0.77 | PDGFRB (0.72) | PDGFRBPDGFRASRCTGFBR1EGFR | |
| SCHEMBL28722262 | 0.77 | NR4A2 (0.47) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL24250089 | 0.76 | SRC (0.50) | PDGFRBPDGFRASRCTGFBR1EGFR | |
| Amiquinsin SCHEMBL242841 | 0.75 | EHMT2 (0.63) | PDGFRBPDGFRASRCEGFRKDR | |
| SCHEMBL14908846 | 0.75 | PDPK1 (0.51) | PDGFRBPDGFRAKDRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| CN-114195805-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022017368-A1 | DNA-PK SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 首药控股(北京)股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| EP-3807278-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PDGFRB 1414/4885PDGFRA 1129/4885SRC 3936/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PDGFRB 1209/4885PDGFRA 1019/4885SRC 3902/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | PDGFRB 1414/4885PDGFRA 1129/4885SRC 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.